Johnson & Johnson (JNJ)
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
I have invested in dividends for 20 years. These stocks are my top dividend compounders of all time
In the world of investing, dividends have long been a popular way to earn income alongside growth opportunities with stocks.
Johnson & Johnson Stock To $134?
Our machine-driven multifactor analysis suggests it may be time to sell JNJ stock, as we hold a pessimistic outlook with a potential target price of $134. The company's Moderate operating performance and financial health, combined with its High valuation, make the stock appear Unattractive.
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
J&J projects faster 2026 growth in Innovative Medicine and MedTech, topping consensus estimates on both revenues and EPS.
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
Recent market speculation linking Johnson & Johnson NYSE: JNJ to a complete acquisition of its partner, Protagonist Therapeutics NASDAQ: PTGX, offers a valuable glimpse into a core corporate strategy. For a healthcare sector giant of Johnson & Johnson's scale, such moves are not about chasing short-term stock pops.
Johnson & Johnson faces UK lawsuit over talcum baby powder
A group of around 3,000 people in the UK has filed a legal claim against Johnson & Johnson (NYSE:JNJ), accusing the pharmaceutical company of selling talcum-based baby powder contaminated with asbestos. The case draws on internal documents and scientific studies dating back to the 1960s, which allegedly show the company knew its product contained minerals such as tremolite and actinolite.
J&J faces first UK lawsuits alleging its baby powder caused cancer
Johnson & Johnson is facing the first lawsuits in Britain over allegations that its talc products cause cancer, as it fights tens of thousands of similar claims in the United States.
Johnson & Johnson's MedTech spin-off could boost focus, Bank of America says
Bank of America maintained a ‘Neutral' rating on Johnson & Johnson (NYSE:JNJ) after the company posted third-quarter results slightly above expectations and hinted at a strategic MedTech shake-up. In a note Wednesday, the bank highlighted that J&J's third-quarter revenue and earnings per share beat consensus by roughly 1%, driven largely by stronger-than-expected performance from its Stelara biologic.
Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off
Johnson & Johnson's NYSE: JNJ stock price can continue to advance because its strategy to reinvigorate growth and widen margins is working. The plan centers on divesting underperforming healthcare businesses to focus on higher-margin, more potent growth markets.
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q3 2025 Earnings Call October 14, 2025 8:30 AM EDT Company Participants Darren Snellgrove - Vice President of Investor Relations Joaquin Duato - CEO & Chairman Joseph Wolk - Executive VP & CFO Jennifer Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Tim Schmid - Executive VP & Worldwide Chairman of MedTech John Reed - Executive Vice President of Innovative Medicine, R&D Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Danielle Antalffy - UBS Investment Bank, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Terence Flynn - Morgan Stanley, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Matthew Miksic - Barclays Bank PLC, Research Division David Risinger - Leerink Partners LLC, Research Division Presentation Operator Good morning, and welcome to Johnson & Johnson's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded.
